Clinical trial
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With…
NCT00453102 · University of Miami, Other · Completed
Key facts
| NCT number | NCT00453102 |
|---|---|
| Title | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma |
| Official title | Phase II Study of Ibritumomab Tiuxetan (Zevalin®) in Patients With Previously Untreated Marginal Zone Lymphoma |
| Lead sponsor | University of Miami, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Marginal Zone Lymphoma |
| Intervention type | Drug |
| Interventions | Rituximab, Ibritumomab Tiuxetan |
| Enrollment | 18 |
| Start date | Feb 1, 2006 |
| Primary completion | Feb 1, 2015 |
| Completion | Feb 1, 2015 |
| First posted | Mar 28, 2007 |
| Last update posted | Jan 1, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: